Surgery Partners SGRY
- Market cap
- $2.1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.6×
- EV/EBIT
- 18.2×
- Revenue, 12 months
- $3.4B
- +4% on a year ago
- Net margin
- −2.6%
- Free cash flow yield
- 9.1%
Surgery Partners trades at 0.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $3.4B over the last twelve months, up 4% on a year earlier with a −3% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $674.1M+9% | $735.4M+4% | $717.4M+8% | $762.1M+14% | $770.4M+14% | $864.4M+18% | $776M+8% | $826.2M+8% | $821.5M+7% | $885M+2% | $810.9M+5% | $848.9M+3% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| SG&A | $36.8M+106% | $20.9M−27% | $33.2M+4% | $40.3M+29% | $29.2M−21% | $36M+72% | $36M+8% | $36.1M−10% | $22.4M−23% | $23.7M−34% | $39.3M+9% | $36.3M+1% |
| $82.6M+12% | $101.4M+8% | $76M+64% | $84.8M−13% | $60.9M−26% | $127.1M+25% | $61.9M−19% | $111.7M+32% | $105.7M+74% | $110.2M−13% | $65.8M+6% | $102.1M−9% | |
| Interest expense | $49.8M−18% | $48.7M−20% | $47.3M+1% | $51.5M+8% | $50M+0% | $52.9M+9% | $62.2M+32% | $67.9M+32% | $74.9M+50% | $67.6M+28% | $69.1M+11% | $69.8M+3% |
| Pre-tax income | $32.8M+145% | $52.7M+59% | $28.7M | $33.3M−33% | $10.9M−67% | $74.2M+41% | −$300K | $43.8M+32% | $30.8M+183% | $42.6M−43% | −$3.3M+1000% | $32.3M−26% |
| $3.1M−60% | $6M−39% | $4.4M | $4.9M | $4.5M+45% | $120.8M+1913% | $0 | −$1.1M | $5.5M+22% | $13.6M−89% | −$1.2M | $2.6M | |
| Net income | −$4.9M−80% | −$1M−96% | −$12.4M−50% | −$15.5M | −$31.7M+547% | −$108.5M+10750% | −$37.7M+204% | −$2.5M−84% | −$22.7M−28% | −$15M−86% | −$35.9M−5% | −$15M+500% |
| −$0.04−86% | −$0.01−96% | −$0.10−50% | −$0.12 | −$0.25+525% | −$0.86+8500% | −$0.30+200% | −$0.02−83% | −$0.18−28% | −$0.12−86% | −$0.28−7% | −$0.12+500% | |
| 125.7M+41% | 125.8M+23% | 126M+1% | 126.1M−1% | 126.2M+0% | 126.2M+0% | 126.6M+1% | 127M+1% | 127.2M+1% | 128M+1% | 128.4M+1% | 128.8M+2% |
Gross profit: 22 periods, Q1 FY14 to Q4 FY19: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY14 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 9 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY15 and Q4 FY16: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Surgery Partners' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SGRYSurgery Partners | $2.1B | n/m | 84.3× | 0.6× | +4% | −2.6% | |
| PGNYProgyny | $2.2B | 31.5× | 55.1× | 1.7× | +6% | 6.0% | |
| ADUSAddus HomeCare | $2.3B | 21.4× | 32.4× | 1.5× | +16% | 7.1% | |
| MDPediatrix Medical | $2.4B | 14.0× | 13.4× | 1.2× | +1% | 9.0% | |
| HCSGHealthcare Services | $1.7B | 14.7× | 26.1× | 0.9× | +4% | 6.6% | |
| ARDTArdent Health | $1.7B | 22.3× | 8.5× | 0.3× | +3% | 1.2% | |
| PRVAPrivia Health | $2.9B | 107× | 158× | 1.2× | +24% | 1.2% | |
| PNTGPennant | $1.5B | 46.5× | 47.0× | 1.3× | +38% | 2.9% | |
| AVAHAveanna Healthcare | $2.9B | 10.9× | 21.8× | 1.1× | +20% | 10.6% | |
| USPHU S Physical Therapy | $1.3B | 101× | 42.1× | 1.6× | +11% | 4.0% | |
| OMDAOmada Health | $1.2B | 316× | 341× | 3.7× | +48% | 1.4% | |
| Peer median | $2B | 26.9× | 37.2× | 1.3× | +14% | 5.0% |
More on Surgery Partners
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #10of 45Hospital and care facility stocks with the lowest price to sales ratio
- #9of 32Hospital and care facility stocks with the highest free cash flow yield
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .